Is BeiGene (06160.HK) a stock worth buying? A latest outlook on its stock performance.
Real-time quote
HK$176.800Hong Kong dollar
Today's Performance
BeiGene (06160.HK) is a global, commercial-stage biotechnology company focused on the research, development, manufacturing, and commercialization of innovative medicines.
For investors, the core of investment decision‑making lies in accurately assessing a company’s growth potential. So, is the current 06160.HK actually worth buying?As a leading financial information service provider, Futubull integrates rating information on each stock from numerous renowned global securities research institutions.It aims to provide users with a comprehensive and timely view of market consensus, helping you accurately identify the optimal entry point.
■According to the latest [Major Brokerage Ratings] data compiled by Futubull (as of April 24, 2026)
Total8A leading analyst has been involved in the rating of 06160.HK.Overall Rating：【Strong Buy】
Futubull provides you with professional stock analysis and investment decision support.
In addition to ratings from professional institutions, Futubull takes you, from the perspective of a professional investor, to utilize the “Three-Step Analysis Method” to...Company business, performance status, and technical indicatorsThree core dimensions for a deep dive into stocks, helping you determine whether 06160.HK is worth buying.
■Company Business: What Does BeiGene Do?
BeiGene, Ltd. (06160.HK) is a global, commercial-stage biotechnology company founded in 2010 and incorporated in Switzerland. The company focuses on the research, development, manufacturing, and commercialization of innovative oncology drugs. BeiGene is listed on the Nasdaq Stock Market in the United States, the Main Board of the Hong Kong Stock Exchange, and the STAR Market of the Shanghai Stock Exchange, with approximately 12,000 employees worldwide. Its operations span the entire value chain, from early-stage drug discovery to global commercialization.
Independently developed and commercialized drugs
The company is focused on the independent R&D and commercialization of innovative oncology drugs. Its core products include Brukinsa® (zanubrutinib), a BTK inhibitor indicated for the treatment of multiple hematologic malignancies, and Tislelizumab® (tiragolumab), a PD-1 antibody approved for the treatment of various solid tumors, which together constitute the primary source of its product revenue.
Product Collaboration and Licensing Revenue
The company expands its product portfolio and market coverage through strategic collaborations, such as its partnership with Amgen on several oncology products in Mainland China. The company's "net collaboration revenue" comes from such licensing agreements and partnerships, complementing its internal R&D.
Global Clinical Development Platform
The company has established a global clinical development platform and conducts clinical trials across six continents. With more than 80 preclinical programs in its pipeline, it continuously advances candidate drugs into the clinical stage, with a strong focus on innovative therapies for hematologic malignancies and solid tumors.
Futubull tooltip:
Facing fragmented information, want to quickly grasp the key priorities of your company’s business?
Simply open the Futubull app, tap the “Company” tab, and scroll down to view BeiGene’s “Business Segment Breakdown,” where you can clearly and intuitively see BeiGene’s main businesses, core products, and market share, helping you quickly analyze the company’s fundamentals.
Futubull breaks down the core business of listed companies for you, helping you understand their fundamentals.
■Performance Dimension: Is BeiGene Making Money?
Futubull's "Earnings Calendar" shows that BeiGene has… 2026/5/6Publish 2026 Q1Performance.
At the same time, Futubull’s “Performance Express” module has compiled the following key performance data for your reference:
| Project | Core data for the quarter | Key changes |
|---|---|---|
| Total Operating Revenue | US$1.498 billion | Growing 32.84% year-on-year, exceeding market expectations of $1.458 billion. |
| Operating profit | US$185 million | Grew 332.97% year-on-year, exceeding market expectations of US$158 million. |
| Profit attributable to shareholders | US$66.502 million | A year-on-year increase of 143.79% |
| Cash flow from operating activities | US$417 million | A year-on-year increase of 455.28% |
Baiji Shenzhou's latest financial results have been released, but with such a dense pile of financial reports, do you find it hard to read them in detail—and even more challenging to quickly assess what the data actually means?Major positive newsStillHidden RisksIf you lack the proper interpretation of financial reports, you’ll miss out.Best buying and selling pointsIf there were a reliable tool to help interpret financial reports, it would greatly assist you during earnings season.Seize the initiative and reap profits with ease.。
Futubull's "Performance Express" feature:
Transform complex financial reports into clear, concise insights, enabling you to grasp key data such as revenue and earnings per share—and determine within minutes whether these figures “exceeded expectations” or “fell short of market expectations.”
✓ Positive signal:If the earnings report shows that revenue and net profit significantly outperform market expectations, it generally indicates strong underlying fundamentals for the company. Investors can assess current market conditions and their own risk tolerance to identify potential investment opportunities or make appropriate adjustments to their portfolios.
✓ Risk signal:If key financial indicators show weak performance (or all decline), and both revenue and earnings per share fall short of expectations, this may signal a slowdown in growth. Investors should carefully assess the risks associated with their holdings and, in light of their investment strategies, consider adjusting their portfolio allocations or adopting a wait-and-see approach.
In short, regardless of whether the performance is good or bad, Futubull’s “Performance Express” feature can instantly interpret key data for you, allowing you to confidently enter the market and place orders without having to painstakingly pore over densely packed financial reports.
Open the Futubull App > Individual Stock Page > [Company] Tab—Performance Express—to use this feature for free!
Futubull dissects key financial report data to help you identify buying and selling opportunities before and after earnings releases.
■Technical Indicators: What is the current market sentiment toward BeiGene?
The financial data analyzed in “Performance Express” can help you gain a clear understanding of a company’s long‑term growth potential and underlying value; however, to accurately time your entry into a complex market, you still need…Technical IndicatorsProvided real-time signals. Only by anchoring long-term direction with fundamental analysis and locking in short-term opportunities with technical analysis can investment decisions become more stable and more accurate.
BeiGene (06160.HK) currently shows 1 "buy signal" and 2 "sell signals."
"Optimistic"The WMSR has moved from the neutral zone into oversold territory, suggesting that prices may soon rebound.
Let it go.The closing price has fallen below the middle Bollinger Band, indicating that downward pressure may persist.
Let it go.The price has fallen below the 20-day moving average, suggesting that the downtrend may continue.
For those of you who have to return to work and attend meetings on a daily basis, even though you know that the MACD and RSI are crucial, do you simply not have time to monitor the market around the clock? Or perhaps you’re worried about misinterpreting the indicators and can’t tell the difference between...“True Signal”Still"False Breakout"？No need to slog through technical theories—just let “NiuNiu AI” instantly translate market conditions for you!
Futu SupportAI Real‑Time MonitoringIncluding 15 key indicators such as MACD, KDJ, and RSI, these tools directly “translate” complex chart patterns into simple signals—so you no longer need to delve into what “golden crosses and death crosses” or “top and bottom divergences” actually mean, and you can…Easily Grasp Technical Trends。
After understanding BeiGene’s technical analysis and forming a preliminary judgment on the overall price trend, to ensure you can react swiftly at critical moments, you may consider using Futubull’s…Price AlertFunction: You can set the following alerts for key areas:
✓ Stock Price Alert: Set up to receive instant notifications when the price breaks above HK$184.0 or falls below HK$177.0.
✓ Indicator AlertSet a notification to trigger when RSI(6) breaks above 50 or falls below 30.
With Futubull AI, you’ll never have to worry about complex technical indicators again! Download Futubull now and let AI translate technical analysis into clear buy/sell signals—easily distinguishing between “bullish” and “bearish.” Investing has never been so simple and straightforward!
AI-powered real-time interpretation of technical indicators—master buying and selling timing.
■Why do investors choose Futu for trading?
Investing is never a one‑time deal; it's a journey that requires long‑term tracking and dynamic adjustments. Perhaps you don't yet have enough capital to buy BeiGene, or perhaps BeiGene isn't yet worth buying now, but you can still use Futubull to track BeiGene over the long term.
Open Futubull,Add BeiGene to your wishlist., you will also reap
Performance Release Reminder：
Before each round of BeiGene's earnings release, Futubull will send you a reminder so you don't miss any earnings opportunity.
Related News Feed：
Real‑time aggregation of major news such as product launches and board changes, enabling you to promptly capture the key events that impact BeiGene's stock price.
Institutional Holdings Changes：
Track the flow of "smart money" and gain instant insights into the buying and selling activities of major banks and funds in BeiGene.
Stock Price Alert：
Set your desired "psychological price point" and enjoy peace of mind without having to monitor the market around the clock—once BeiGene's stock price pulls back, the system will send you an immediate notification.
All of the above functions“Free of charge”, download Futubull now and start your professional investment journey!
●Why choose Futu?
Security Assurance
Futu is subject toDual protection from the Hong Kong Investor Compensation Fund (up to HK$500,000) and the U.S. SIPC (up to US$500,000)., all client assets are…Independent Bank Custodyand is equipped with a risk management system developed in-house to ensure data security.
Licensed and compliant
Futu Securities International (Hong Kong) Co., Ltd. isHong Kong’s largest tech-driven brokerage firm (stock code: FUTU)It is also a licensed corporation approved by the Securities and Futures Commission of Hong Kong (CE No.: AZT137).
The company is strictly regulated by the China Securities Regulatory Commission and holds licenses of Class 1, 2, 3, 4, 5, 7, and 9.
Zero-commission trading
Hong Kong stocks, U.S. stocks fractional shares, Crypto0% commission on trades,Help you invest and save more!
Open an account now and enjoy a welcome bonus worth over 1,000 yuan!
Track BeiGene's developments for free and trade Hong Kong/US stocks securely and in compliance with regulations.
The content presented above were generated by AI language model with publicly available information and the above material does not represent the position of the company and shall not constitute any investment advice. You may only use the materials on this website for personal reference and non-commercial purposes. Read More
